Mode
Text Size
Log in / Sign up
Phase 2 Completed N=175 Randomized Double-blind Treatment

The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment

Source: ClinicalTrials.gov NCT01667406 ↗
Enrolled (actual)
175
Serious AEs
5.1%
Results posted
Jun 2021
Primary outcomePrimary: Percentage of Oocyte Maturation — 49; 36; 76; 103 percentage of expected oocyte yield — p=<0.05

Summary

We want to find out if kisspeptin is successful in stimulating oocyte maturation when it is used as a 'trigger' injection during IVF therapy for infertility.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Oocyte Maturation
49; 36; 76; 103; 53; 86 <0.05 sig
SECONDARY
Biochemical Pregnancy
1; 1; 11; 8; 1; 10
SECONDARY
Occurrence of OHSS
0; 0; 0; 0; 0; 0
SECONDARY
Fertilization Rate
14.28; 58.33; 66.94; 76.01; 68; 76
SECONDARY
Embryo Formation
0; 2.33; 3.8; 4.5; 5.8; 9.4
SECONDARY
Number of Participants With Clinical Pregnancy
1; 0; 7; 4; 1; 10

Eligibility Criteria

Inclusion Criteria

  • Aged 18 - 34 years
  • Body mass index between 18 and 29 kg/m2
  • Stable body weight for at least 3 months
  • Normal early menstrual cycle follicular phase serum FSH concentration
  • Serum anti-Mullerian hormone (AMH) > 40pmol/L
  • No more than one previous IVF treatment cycle
  • Both ovaries intact

Exclusion Criteria

History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or potentially cause harm to the volunteer

  • Without access at home to a telephone, or other factor likely to interfere with ability to participate reliably in the study
  • Treatment with an investigational drug within the preceding 2 months
  • Donated blood during the preceding 3 months or intention to do so before the end of the study
  • Previous poor response to IVF treatment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01667406). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search